Q: What exactly is DSIP?
A: Delta Sleep Inducing Peptide is a small synthetic peptide that has been studied for several biological effects, including possible involvement in sleep and neuroendocrine regulation.
Q: Does DSIP treat insomnia?
A: DSIP should not be considered an established treatment for insomnia. Human research is limited and has produced mixed results, so individual outcomes cannot be predicted.
Q: What does the research say about sleep?
A: Small human studies have reported changes in certain measures of sleep, while other research found limited clinical significance. More evidence is needed to establish its effectiveness for sleep-related conditions.
Q: How is DSIP administered?
A: DSIP is given by subcutaneous injection according to the individualized instructions provided by our healthcare provider. The prescribed dose and treatment period should be followed exactly.
Q: How long is a DSIP treatment plan?
A: The supplied protocol uses an initial period of approximately 4–8 weeks. Our healthcare provider will determine the appropriate duration and whether treatment should continue.
Q: Is DSIP FDA-approved for sleep?
A: No. DSIP is not an FDA-approved treatment for insomnia or other sleep disorders. Its potential uses remain investigational.